Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Wugen

Main focus: Off-the-shelf cellular therapies for cancer treatment

Company stage: Clinical

Diseases: T-cell acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), head and neck cancer, melanoma

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: San Diego, CA, USA and St. Louis, MO, USA

Website: https://www.wugen.com/

Pipeline: https://www.wugen.com/pipeline/

Wugen is a privately held biotech company. The company focuses on developing CAR-T and natural killer (NK) cells to kill malignant T cells and solid tumours. Wugen uses CRISPR for the deletion of the T-cell receptor (TCR), which enables the use of T cells from healthy donors without the risk of graft-versus-host disease.

Tags

HashtagWUGEN Inc.

Company: Wugen
close
Search CRISPR Medicine